Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
6.83
-0.65 (-8.69%)
At close: Mar 3, 2025, 4:00 PM
6.25
-0.58 (-8.49%)
After-hours: Mar 3, 2025, 7:01 PM EST
Emergent BioSolutions Employees
Emergent BioSolutions had 1,600 employees as of December 31, 2023. The number of employees decreased by 900 or -36.00% compared to the previous year.
Employees
1,600
Change (1Y)
-900
Growth (1Y)
-36.00%
Revenue / Employee
$703,438
Profits / Employee
-$130,500
Market Cap
370.08M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
EBS News
- 13 days ago - Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewsWire
- 24 days ago - Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans - GlobeNewsWire
- 6 weeks ago - Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions: Stock Is A Likely Winner In 2025 - Seeking Alpha
- 6 weeks ago - Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - GlobeNewsWire
- 7 weeks ago - Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - GlobeNewsWire
- 7 weeks ago - Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - GlobeNewsWire
- 7 weeks ago - Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - GlobeNewsWire